Clinical trial
3-AP in Treating Patients With Advanced Prostate Cancer
NCT00054015 · Vion Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00054015 |
|---|---|
| Title | 3-AP in Treating Patients With Advanced Prostate Cancer |
| Official title | A Phase II Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) in Patients With Advanced Prostate Cancer |
| Lead sponsor | Vion Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | triapine |
| Start date | Dec 1, 2002 |
| Completion | Jan 1, 2008 |
| First posted | Feb 6, 2003 |
| Last update posted | Nov 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: